FDA to review GSK's depemokimab.

Pharmaceutical giant GSK said on Monday that the US Food and Drug Administration has agreed to review its Biologics License Application for the use of its depemokimab asset in two indications.

GSK
03 March 2025 09:27:26

Source: Sharecast

GSK said the proposed indications were as add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids plus another asthma controller and, as add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.

The London-listed firm stated the submission of depemokimab for review was based on data from positive SWIFT and ANCHOR trials, which showed reduced exacerbation and hospitalisation rates, as well as early and sustained reductions in nasal polyp size and nasal obstruction versus placebo.

If approved, depemokimab will be the first ultra-long-acting biologic with a six-month dosing.

As of 0925 GMT, GSK shares were up 0.61% at 1,475.50p.

Reporting by Iain Gilbert at Sharecast.com

FTSE 100 ( UKX )

ISIN: N/A

Exchange: London Stock Exchange

Sell:

0.00

Buy:

0.00

Change: 20.36 ( 0.24 %)

Date:

30/04/2025 - 08:05

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.